Single User
£3698
PDF
74 pages

Chronic Kidney Disease (CKD) Forecast in 19 Major Markets 2016-2026


Chronic kidney disease (CKD), also known as chronic renal disease, is characterised by progressive loss of kidney function over time. CKD is defined as persisting kidney damage or a glomerular filtration rate (GFR) of <60 mL/min/1.73 m2 for ≥ 3 months. This damage refers to any renal pathology that has the potential to cause a reduction in renal functional capacity, such as GFR.

This report provides the current prevalent population for CKD across 19 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Turkey, Mexico, Australia, Canada, Norway, Ireland, Netherlands, Poland, South Korea and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of CKD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for CKD include:

  • Hypertension
  • Diabetes
  • Chronic heart failure
  • Anaemia
  • Hyperphosphatemia
  • Increased risk of infection
  • End stage renal disease
  • Acute kidney injury

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global CKD’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of CKD and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on CKD’s prevalent population.
  • Identify sub-populations within CKD which require treatment.
  • Gain an understanding of the specific markets that have the largest number of CKD patients.
Table of Contents
  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
    • Additional data available on request
  • Top-Line Prevalence for Chronic Kidney Disease
  • Features of Chronic Kidney Disease Patients
    • CKD by Stage of Disease
    • ESRD Therapy
    • Associated Conditions of CKD Patients
    • Associated Conditions of ESRD Patients
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix
List of Tables
  • National Kidney Foundation’s CKD KDOQI Clinical Practice Guidelines for CKD
  • Prevalence of CKD, total (000s)
  • Prevalence of CKD, males (000s)
  • Prevalence of CKD, females (000s)
  • Stage of CKD patients, total (000s)
  • Renal replacement therapy in Stage V (ESRD) CKD patients, total (000s)
  • Prevalence of diabetes in CKD, total (000s)
  • Prevalence of elevated CRP in CKD, total (000s)
  • Prevalence of myocardial infarction in CKD, total (000s)
  • Prevalence of diabetes in ESRD patients, total (000s)
  • Prevalence of hypertension in ESRD patients, total (000s)
  • Prevalence of glomerulonephritis in ESRD patients, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of CKD by 5-yr age cohort, males (000s)
  • USA Prevalence of CKD by 5-yr age cohort, females (000s)
  • France Prevalence of CKD by 5-yr age cohort, males (000s)
  • France Prevalence of CKD by 5-yr age cohort, females (000s)
  • Germany Prevalence of CKD by 5-yr age cohort, males (000s)
  • Germany Prevalence of CKD by 5-yr age cohort, females (000s)
  • Italy Prevalence of CKD by 5-yr age cohort, males (000s)
  • Italy Prevalence of CKD by 5-yr age cohort, females (000s)
  • Spain Prevalence of CKD by 5-yr age cohort, males (000s)
  • Spain Prevalence of CKD by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of CKD by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of CKD by 5-yr age cohort, females (000s)
  • Brazil Prevalence of CKD by 5-yr age cohort, males (000s)
  • Brazil Prevalence of CKD by 5-yr age cohort, females (000s)
  • Japan Prevalence of CKD by 5-yr age cohort, males (000s)
  • Japan Prevalence of CKD by 5-yr age cohort, females (000s)
  • India Prevalence of CKD by 5-yr age cohort, males (000s)
  • India Prevalence of CKD by 5-yr age cohort, females (000s)
  • Turkey Prevalence of CKD by 5-yr age cohort, males (000s)
  • Turkey Prevalence of CKD by 5-yr age cohort, females (000s)
  • Mexico Prevalence of CKD by 5-yr age cohort, males (000s)
  • Mexico Prevalence of CKD by 5-yr age cohort, females (000s)
  • Australia Prevalence of CKD by 5-yr age cohort, males (000s)
  • Australia Prevalence of CKD by 5-yr age cohort, females (000s)
  • Canada Prevalence of CKD by 5-yr age cohort, males (000s)
  • Canada Prevalence of CKD by 5-yr age cohort, females (000s)
  • Norway Prevalence of CKD by 5-yr age cohort, males (000s)
  • Norway Prevalence of CKD by 5-yr age cohort, females (000s)
  • Ireland Prevalence of CKD by 5-yr age cohort, males (000s)
  • Ireland Prevalence of CKD by 5-yr age cohort, females (000s)
  • Netherlands Prevalence of CKD by 5-yr age cohort, males (000s)
  • Netherlands Prevalence of CKD by 5-yr age cohort, females (000s)
  • Poland Prevalence of CKD by 5-yr age cohort, males (000s)
  • Poland Prevalence of CKD by 5-yr age cohort, females (000s)
  • South Korea Prevalence of CKD by 5-yr age cohort, males (000s)
  • South Korea Prevalence of CKD by 5-yr age cohort, females (000s)
  • China Prevalence of CKD by 5-yr age cohort, males (000s)
  • China Prevalence of CKD by 5-yr age cohort, females (000s)
Australia, Brazil, Canada, China, France, Germany, India, Ireland, Italy, Japan, Mexico, Netherlands, Norway, Poland, Republic of Korea, Spain, Turkey, United Kingdom, United States of America